Goodpath Partners With GiftHealth to Expand Access to GLP-1 Therapies Through LillyDirect

Goodpath, a virtual clinic for chronic health conditions, has reached a pharmacy integration deal with GiftHealth, Eli Lilly and Company’s LillyDirect pharmacy provider.¹ LillyDirect is Lilly’s direct-to-consumer digital healthcare platform that was launched back in January 2024.² It’s known for providing resources for disease management, featuring access to independent healthcare providers, support, and direct home delivery of certain Lilly medicines through third-party pharmacy dispensing services.

The goal of this partnership is to help qualified Goodpath members with simplified access to Zepbound (tirzepatide), if prescribed by their provider of course. Goodpath’s comprehensive, whole-person care programs offer personalized support that addresses members’ physical, mental, and lifestyle health needs. Eligible participants in any Goodpath condition pathway can access GLP-1 support when prescribed.

Comprehensive, whole-person care approach

These members who are prescribed a GLP-1 will have access to physician teams that advise on the proper use of the drug, ways to manage side effects, and adherence support. With monitoring of the patient journey being essential, members and Goodpath care teams are able to monitor fill status and pharmacy updates over the course of the entire fulfillment journey.

“We’re committed to supporting individuals with effective, sustainable weight care,” said Bill Gianoukos, CEO and founder, Goodpath. “We’re reducing barriers to care and supporting individuals prescribed clinically appropriate medications, while also delivering wraparound care to manage side effects, build healthy routines, and address related conditions like sleep, stress, and joint pain. Medications are powerful tools, and they deliver the most benefit when supported by comprehensive care that addresses the whole person.”

Goodpath offers an AI-supported, multi-condition care program that helps members achieve weight goals while managing related chronic health needs such as diabetes, pain, digestive health, sleep, mental health, and cancer survivorship. Members receive personalized coaching, shipped care kits, and unlimited clinical guidance, all integrated into a single, comprehensive care platform. Its partnership with GiftHealth highlights a common mission to expand access to transformative treatments.

“When we remove barriers between people and the treatments that can change their lives, we move healthcare closer to what it should be: human, accessible, and built around the needs of those it serves,” noted Robert Hoppe, GiftHealth’s EVP of life sciences. “Supporting this work with Goodpath is part of our commitment to reshaping how care reaches people, at a time of growing demand for accessible solutions.”

GLP-1 market shifts and affordability debates

This news comes at a time when GLP-1 demand has been surging worldwide. Eli Lilly is increasing the UK list price of its GLP-1 drug Mounjaro by 170%.³ The company attributes the move to aligning prices with the therapy’s value and global market conditions, but the hike has sparked debate over affordability and access.

Meanwhile, Novo Nordisk recently filed 14 new lawsuits intended to protect patients from unapproved compounded drugs that falsely claim to contain semaglutide.⁴ The defendants that are mentioned in the lawsuits claim that these compounded products have been both reviewed and approved by the FDA, or are just as effective as manufacturer’s approved semaglutide products.

Novo Nordisk intensifies legal action against compounded semaglutide

According to the lawsuits, telehealth providers are infringing upon state corporate practice of medicine laws by not only unfittingly impacting doctors’ decisions, but guiding patients to take the counterfeit compounded semaglutide. These products have reportedly unapproved knockoffs not been approved as safe and effective, and have potentially been created using banned foreign active pharmaceutical ingredients (APIs).

“Patients deserve safe, effective treatments from companies they can trust. No one should have to gamble with their health by using knockoff drugs made with ingredients that lack oversight and safety standards,” said Dave Moore, executive vice president, US Operations of Novo Nordisk Inc. “Novo Nordisk is addressing this issue through education, advocacy, and legal action against businesses that mislead Americans and jeopardize their health with unsafe and unapproved knockoffs. We urge regulators to enforce laws designed to protect public health.”

References

1. Goodpath Adds Self-Pay GLP-1 Option Through Integration with LillyDirect Pharmacy Provider GiftHealth. PR Newswire. August 14, 2025. Accessed August 15, 2025. https://www.prnewswire.com/news-releases/goodpath-adds-self-pay-glp-1-option-through-integration-with-lillydirect-pharmacy-provider-gifthealth-302529567.html

2. Eli Lilly Announces New Telehealth, Home Delivery Option for Popular Weight Loss Drug. Pharmaceutical Commerce. January 5, 2024. Accessed August 15, 2025. https://www.pharmaceuticalcommerce.com/view/eli-lilly-announces-new-telehealth-home-delivery-option-for-popular-weight-loss-drug

3. Hollan M. Eli Lilly Announces 170% Price Increase for Mounjaro in UK. Pharmaceutical Commerce. August 14, 2025. Accessed August 15, 2025. https://www.pharmexec.com/view/eli-lilly-170-percent-price-increase-mounjaro-uk

4. Saraceno N. Novo Nordisk Ramps Up Legal Fight Against Compounded Semaglutide Knockoffs. Pharmaceutical Commerce. August 6, 2025. Accessed August 15, 2025. https://www.pharmaceuticalcommerce.com/view/novo-nordisk-legal-fight-compounded-semaglutide-knockoffs